Exosens Shares Bounce Back 2.5% After Record Deal with Czech Army
The French night vision technology specialist regains momentum in mid-morning trading, driven by the announcement of a long-term agreement with the Czech armed forces. The rebound comes after several sessions of correction that brought the stock close to its technical support.
A Record Contract with Prague Until 2032 Revives the Stock
Exosens shares gain 2.59% to €55.55 during the session, while the SBF 120 drops 0.36%. The stock is among the top gainers in the SBF 120, although not leading the segment, which is occupied by Soitec. The movement reflects the multi-year agreement signed with Brolis to supply the Czech armed forces with about 17,000 image intensifier tubes, to be delivered by 2032. Prague has never placed such a large order in this field, providing unusual industrial visibility towards the end of the decade. This rebound follows a challenging period, with the stock losing nearly 20% over a month and 7.57% over the past week, after several documented support breaks in recent days, including one following the securing of a €140 million credit facility from the EIB.
Technical Rebound Initiated on Support at €52.65 with RSI in Oversold Zone
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock price reacts from the support level identified at €52.65, after a slide that had led the stock into an oversold zone. The RSI at 34 indicates this selling exhaustion and accompanies today's rebound, without signaling a lasting reversal at this stage. The medium-term configuration remains fragile: the price is trading below the MM20 (€59.97, a gap of -7.37%) and the MM50 (€61.82, a gap of -10.14%), both levels acting as resistances if the rebound extends. However, the stock maintains above the MM200 (€54.81, a gap of +1.35%), a line that still separates the movement from a more marked degradation. The next area to watch remains the resistance at €69.20, still distant, while the performance over one year remains positive at +37.33%.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.